Test Price
1,000 AED✅ Home Collection Available
Beta Thalassemia‑9 Common Mutations Screening (Couple) – Molecular Genotyping for Carrier Risk Assessment
Executive Summary & Core Metrics
Clinical Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing, using definitive End Point PCR analysis for nine common beta-globin mutations.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Telephonic post-test clinical guidance in result interpretation, ensuring carrier couples make informed reproductive decisions.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This molecular assay directly identifies nine common beta-globin gene mutations in both partners, classifying couples as low‑risk or high‑risk for offspring with Beta Thalassemia Major. Unlike basic CBC evaluations, this targeted genotyping provides definitive carrier status, essential for family planning in the UAE’s high‑risk demographic landscape.
| Specification | Our Assay (Gold Standard) | Closest Alternative (Hb Electrophoresis) |
|---|---|---|
| Precision | Molecular Genotyping (99.9%) | Phenotypic Screening (Limited) |
| Method | End Point PCR | Hemoglobin Quantitation |
| Speed (TAT) | 3–4 Days | 5–7 Days |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasise that this couples‑based screening directly identifies silent carriers through molecular genotyping, enabling accurate risk assessment for autosomal recessive inheritance. Couples with positive results should seek genetic counselling for informed reproductive planning.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Medication Advisory
Do not discontinue any prescribed medication, including iron chelators or folic acid, based solely on this genetic screening report. Always consult your managing specialist for therapeutic decision‑making.
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Incomplete couple pairing (sample from only one partner).
- Exclusion Criteria: Recent allogeneic bone marrow transplant within 6 months prior to blood draw.
- Exclusion Criteria: Active hemodilution from massive transfusion protocol within 72 hours before venipuncture.
- ER Red Flag: This screening is for pre‑conceptional carrier detection; it is not for diagnostic confirmation in symptomatic individuals. If severe pallor, lethargy, or poor feeding is observed in a child, proceed to emergency care immediately.
Patient FAQ & Clinical Guidance
1. Why is the Beta Thalassemia‑9 Mutation Screen crucial for couples in the UAE rather than a routine CBC?
This 9‑mutation PCR panel definitively identifies silent carriers who possess normal hemoglobin levels on routine CBC, preventing missed diagnoses. A standard CBC quantifies hemoglobin volume but cannot resolve the molecular genotype. Only targeted genotyping can determine carrier status, a necessity mandated by UAE pre‑marital counselling guidelines to mitigate the high regional prevalence of beta‑thalassemia alleles. Carrier couples receive precise reproductive risk odds, facilitating informed decisions backed by molecular certainty.
2. What are the UAE regulatory requirements for this genetic test for couples?
This analysis requires a valid prescription from a DHA‑licensed physician, in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability. The prescription is not required for surgery, pregnancy cases, or persons planning to travel abroad. Full adherence to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) is guaranteed for all samples and sensitive genetic information.
3. What is the sample logistics process, and how does the facility ensure cold‑chain integrity?
Our ISO 9001:2015 certified VIP phlebotomists dispatch peripheral blood in validated coolers at 2–8°C, ensuring nucleic acid stability until extraction. Collection is available from 8 AM to 11 PM across all Emirates. The pre‑analytical stability of EDTA whole blood is strictly monitored, with all transit temperatures logged. Patients must present a valid Emirates ID and the DHA‑compliant prescription (if applicable) prior to venipuncture.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Compliance
All genetic data collected during this screening are processed strictly in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and data security protocols are enforced at every stage, from sample collection to result delivery. The facility holds DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | Beta Thalassemia‑9 Common Mutations Screening (Couple) |
| Price (AED) | 1,000 |
| Turnaround Time | 3–4 Days |
| Sample Type / Matrix | Peripheral Blood (EDTA Whole Blood) |
| Methodology Used | End Point PCR |
| ICD‑10‑CM Code | D56.1 (Beta Thalassemia) |
| LOINC Code | 49213-7 (Beta globin gene mutations) |
| DHA Facility License & Laboratory Address | License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians